RenovoRx, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 9.89 million compared to USD 6.32 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 1.21 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | -0.71% | -4.79% | -39.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.30% | 3.35Cr | |
+10.24% | 12TCr | |
+11.73% | 11TCr | |
-6.81% | 2.47TCr | |
-1.31% | 2.2TCr | |
-5.10% | 1.93TCr | |
-11.26% | 1.76TCr | |
-39.36% | 1.73TCr | |
+5.57% | 1.4TCr | |
+33.41% | 1.21TCr |
- Stock Market
- Equities
- RNXT Stock
- News RenovoRx, Inc.
- RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022